NKTR - Nektar Therapeutics Inc. (NKTR) Q1 2024 Earnings Call Transcript

2024-05-09 22:40:25 ET

Nektar Therapeutics, Inc. (NKTR)

Q1 2024 Earnings Conference Call

May 09, 2024, 17:00 ET

Company Participants

Vivian Wu - Associate Director, Investor Relations and Corporate Affairs

Howard Robin - President, CEO & Director

Jonathan Zalevsky - Chief Research & Development Officer

Jennifer Ruddock - Chief Business Officer

Mary Tagliaferri - Chief Medical Officer

Conference Call Participants

Jay Olson - Oppenheimer

Roger Song - Jefferies

Andy Hsieh - William Blair & Company

Arthur He - H.C. Wainwright & Co.

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator Instructions].

I would now like to hand the conference over to your speaker today, Vivian Wu. Please go ahead.

Vivian Wu

Thank you, Crystal, and good afternoon, everyone. Thank you for joining us today. With us on the call are Howard Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; Dr. Mary Tagliaferri, our Chief Medical Officer; and Jennifer Ruddock, our Chief Business Officer. Unfortunately, Sandra Gardiner, our acting Chief Financial Officer, was not able to make it on today's call due to an unexpected family emergency.

On today's call, we expect to make forward-looking statements regarding our business, including statements regarding the therapeutic potential of and future development plans for drug candidates and research programs, the timing of the initiation of clinical studies and the availability of clinical data for drug candidates, the timing and plans for future clinical data presentations, the formation, future development plans or success of our collaboration agreements, the expectations following our corporate restructuring and reorganization, financial guidance, and certain other statements regarding future of our business.

Because forward-looking statements relate to the future, they are subject to uncertainties and risks that are difficult to predict, many of which are outside of our control. Our actual results may differ materially from these statements. Important risks and uncertainties are set forth in our Form 10-K that was filed on March 5, 2024, which is available at SEC.gov....

For further details see: